Allogene Therapeutics, Inc. (NASDAQ:ALLO) Given Average Rating of “Moderate Buy” by Analysts

Allogene Therapeutics, Inc. (NASDAQ:ALLO) has been given a consensus recommendation of “Moderate Buy” by the twelve brokerages that are covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $9.73.

Several research analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Allogene Therapeutics in a report on Friday, November 8th. Piper Sandler dropped their target price on Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Finally, William Blair reaffirmed an “outperform” rating on shares of Allogene Therapeutics in a report on Thursday, November 14th.

Institutional Investors Weigh In On Allogene Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Barclays PLC raised its stake in Allogene Therapeutics by 101.5% in the third quarter. Barclays PLC now owns 342,973 shares of the company’s stock valued at $959,000 after purchasing an additional 172,745 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Allogene Therapeutics by 14.4% in the 3rd quarter. Geode Capital Management LLC now owns 3,227,104 shares of the company’s stock worth $9,037,000 after buying an additional 407,070 shares during the last quarter. MML Investors Services LLC purchased a new stake in shares of Allogene Therapeutics during the 3rd quarter valued at $56,000. Zacks Investment Management bought a new stake in shares of Allogene Therapeutics during the 3rd quarter worth $1,446,000. Finally, EP Wealth Advisors LLC lifted its holdings in shares of Allogene Therapeutics by 125.6% during the 3rd quarter. EP Wealth Advisors LLC now owns 24,475 shares of the company’s stock worth $69,000 after acquiring an additional 13,625 shares during the last quarter. Institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Stock Up 0.5 %

ALLO opened at $2.07 on Wednesday. The firm has a 50-day moving average price of $2.53 and a 200-day moving average price of $2.58. Allogene Therapeutics has a twelve month low of $1.83 and a twelve month high of $5.78. The company has a market capitalization of $434.02 million, a price-to-earnings ratio of -1.33 and a beta of 0.83.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).